Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trialBo Zhang, Binlei Liu, Jing Huang et al.|Journal for ImmunoTherapy of Cancer|2021Cited by 107
A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)Feng Wang, Rui‐Hua Xu, Hui Luo et al.|Clinical Cancer Research|2022Cited by 60
A phase 1/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric/gastroesophageal junction cancer.Chunmei Bai, Jin Li, Junli Xue et al.|Journal of Clinical Oncology|2024Cited by 16
SO-17 A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancerF. Wang, Renjie Xu, Junlan Xiao et al.|Annals of Oncology|2022Cited by 5
A phase III study of comparing FOLFOX+/-bevacizumab with FOLFOX+/-bevacizumab+ high-dose intravenous vitamin C as first-line therapy in patients with advanced colorectal cancer.Feng Wang, Rui‐Hua Xu, Jian Xiao et al.|Journal of Clinical Oncology|2020Cited by 2